Cost-effectiveness of magnetic resonance imaging with a new contrast agent for the early diagnosis of alzheimer's disease

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Biasutti, Maria ^a,b   Dufour, Natacha ^a,b   Ferroud, Clotilde ^a   Dab, William ^a   Temime, Laura ^a  

^a University of Paris Cité   (France)

^b UNIVERSITÉ PARIS EST   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; CONTRAST MEDIUM; CONTRASTOPHORE LINKER PHARMACOPHORE; DONEPEZIL; MEMANTINE; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG COST; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; COST BENEFIT ANALYSIS; DISEASE COURSE; EARLY DIAGNOSIS; ECONOMICS; FEMALE; FRANCE; MALE; METHODOLOGY; MIDDLE AGED;

AGED; ALZHEIMER DISEASE; CONTRAST MEDIA; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; FRANCE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT;

EID: 84859975597     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035559     Document Type: Article

References (55)

1. Alzheimer's Association (2009) 2009 Alzheimer's disease facts and figures. Alzheimers Dement 5: 234-270.
2. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, et al. (2011) Alzheimer's disease. Lancet 377: 1019-1031.
3. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117.
4. Helmer C, Pasquier F, Dartigues JF, (2006) [Epidemiology of Alzheimer disease and related disorders]. Med Sci (Paris) 22: 288-296.
5. Hampel H, Broich K, Hoessler Y, Pantel J, (2009) Biological markers for early detection and pharmacological treatment of Alzheimer's disease. Dialogues Clin Neurosci 11: 141-157.
6. Forlenza OV, Diniz BS, Gattaz WF, (2010) Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med 8: 89.
7. McKhann GM, (2011) Changing concepts of Alzheimer disease. JAMA 305: 2458-2459.
8. Weiner MW, Aisen PS, Jack CR Jr, Jagust WJ, Trojanowski JQ, et al. (2010) The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 6: 202-211 e207.
9. Kulasingam SL, Samsa GP, Zarin DA, Rutschmann OT, Patwardhan MB, et al. (2003) When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia? A decision analysis. Value Health 6: 542-550.
10. McMahon PM, Araki SS, Neumann PJ, Harris GJ, Gazelle GS, (2000) Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. Radiology 217: 58-68.
11. McMahon PM, Araki SS, Sandberg EA, Neumann PJ, Gazelle GS, (2003) Cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology 228: 515-522.
12. Furiak NM, Klein RW, Kahle-Wrobleski K, Siemers ER, Sarpong E, et al. (2010) Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model. BMC Med Inform Decis Mak 10: 24.
13. Moatti JP, Le Corroller Soriano AG, Protiere C, (2003) The "Plan Cancer" in France: an economists' point of view. Bull Cancer 90: 1010-1015.
14. Tan-Torres Edjerer T, Baltussen R, Adam T, Hutubessy R, Acharya A, et al. (2003) WHO guide to cost-effectiveness analysis Geneva World Health Organization.
15. TreeAge Software I (2009) TreeAge Pro Healthcare. Williamstown, USA.
16. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, et al. (2011) APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 16: 903-907.
17. Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, et al. (1999) Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 52: 1138-1145.
18. Fagnani F, Lafuma A, Pechevis M, Rigaud AS, Traykov L, et al. (2004) Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications. Dement Geriatr Cogn Disord 17: 5-13.
19. Himes CL, Wagner GG, Wolf DA, Aykan H, Dougherty DD, (2000) Nursing home entry in Germany and the United States. J Cross Cult Gerontol 15: 99-118.
20. INED (2008) Age- and sex-specific mortality rates, France, 2008 Paris.
21. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, et al. (2001) A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57: 489-495.
22. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50: 136-145.
23. McShane R, Areosa Sastre A, Minakaran N, (2006) Memantine for dementia. Cochrane Database Syst Rev pp. CD003154.
24. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, et al. (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348: 1333-1341.
25. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH, (2008) Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 22: 209-221.
26. Drago V, Babiloni C, Bartres-Faz D, Caroli A, Bosch B, et al. (2011) Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage. J Alzheimers Dis 26 (Suppl 3): 159-199.
27. Blum-Boisgard C, Ulmann P, (2007) Médicaments spécifiques de la maladie d'Alzheimer. Régime Social des Indépendants pp. 1-130.
28. Bowen J, Teri L, Kukull W, McCormick W, McCurry SM, et al. (1997) Progression to dementia in patients with isolated memory loss. Lancet 349: 763-765.
29. Commenges D, Joly P, Letenneur L, Dartigues JF, (2004) Incidence and mortality of Alzheimer's disease or dementia using an illness-death model. Stat Med 23: 199-210.
30. Katz MJ, Lipton RB, Hall CB, Zimmerman ME, Sanders AE, et al. (2011) Age-specific and Sex-specific Prevalence and Incidence of Mild Cognitive Impairment, Dementia, and Alzheimer Dementia in Blacks and Whites: A Report From the Einstein Aging Study. Alzheimer Dis Assoc Disord.
31. Harris GJ, Lewis RF, Satlin A, English CD, Scott TM, et al. (1998) Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine. AJNR Am J Neuroradiol 19: 1727-1732.
32. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, et al. (2009) Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 132: 1310-1323.
33. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, et al. (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5: 228-234.
34. de la Santé Ministère, (2009) Tarifs conventionnels des consultations de médecins spécialistes. In: Santé Mdl, editors. Paris Assurance Maladie, Ministère de la Santé.
35. de la Santé Ministère, (2009) Classification Commune des Actes Médicaux. In: Santé Mdl, editors. Paris Assurance Maladie, Ministère de la Santé.
36. de la Santé Ministère, (2009) Nomenclature des actes de biologie médicale. In: Santé Mdl, editors. Paris Assurance Maladie, Ministère de la Santé.
37. Dictionnaire VIDAL, (2009) Paris Editions du Vidal.
38. Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, et al. (2004) Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology 63: 644-650.
39. Rigaud AS, Fagnani F, Bayle C, Latour F, Traykov L, et al. (2003) Patients with Alzheimer's disease living at home in France: costs and consequences of the disease. J Geriatr Psychiatry Neurol 16: 140-145.
40. Elliott AF, Burgio LD, Decoster J, (2010) Enhancing caregiver health: findings from the resources for enhancing Alzheimer's caregiver health II intervention. J Am Geriatr Soc 58: 30-37.
41. Reimat A, (2002) Production associative et bénévolat informel: quelle signification économique pour les activités de production des retraités? Innovations 15: 73-98.
42. Marbot C, (2008) Travailler pour des particuliers: souvent une activité d'appoint. Insee Références, Les salaires en France.
43. France Bénévolat (2010) La situation du bénévolat en France en 2010. IFOP- France Bénévolat.
44. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, et al. (1993) The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 13: 89-102.
45. Gagnon M, Rive B, Hux M, Guilhaume C, (2007) Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry 52: 519-526.
46. Lejeune C, Bismuth MJ, Conroy T, Zanni C, Bey P, et al. (2005) Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. J Nucl Med 46: 2020-2028.
47. Faissol DM, Griffin PM, Swann JL, (2009) Bias in Markov models of disease. Math Biosci 220: 143-156.
48. Cohen JT, Neumann PJ, (2008) Decision analytic models for Alzheimer's disease: state of the art and future directions. Alzheimers Dement 4: 212-222.
49. Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, et al. (2008) Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46: 1688-1697.
50. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, et al. (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29: 1456-1465.
51. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, et al. (2009) Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 65: 557-568.
52. Reese JP, Hessmann P, Seeberg G, Henkel D, Hirzmann P, et al. (2011) Cost and Care of Patients with Alzheimer's Disease: Clinical Predictors in German Health Care Settings. J Alzheimers Dis.
53. Mauskopf J, Mucha L, (2011) A review of the methods used to estimate the cost of Alzheimer's disease in the United States. Am J Alzheimers Dis Other Demen 26: 298-309.
54. Schachter F, Faure-Delanef L, Guenot F, Rouger H, Froguel P, et al. (1994) Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 6: 29-32.
55. Caselli RJ, Walker D, Sue L, Sabbagh M, Beach T, (2010) Amyloid load in nondemented brains correlates with APOE e4. Neurosci Lett 473: 168-171.